• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Infrequent occurrence of natural mutations in the pp65(495-503) epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates.人巨细胞病毒分离株中，由HLA A*0201等位基因呈递的pp65(495 - 503)表位序列自然突变的发生率较低。
J Virol. 2001 Mar;75(5):2472-4. doi: 10.1128/JVI.75.5.2472-2474.2001.
2
Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles.多种HLA等位基因呈递的巨细胞病毒pp65新型细胞毒性T淋巴细胞表位的鉴定。
Blood. 2004 Jan 15;103(2):630-8. doi: 10.1182/blood-2003-03-0824. Epub 2003 Aug 28.
3
Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes.巨细胞病毒特异性细胞毒性T淋巴细胞识别的巨细胞病毒蛋白pp65内HLA - A24肽表位的鉴定。
Viral Immunol. 2001;14(4):369-77. doi: 10.1089/08828240152716619.
4
Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay.通过计算机算法和酶联免疫斑点测定法高效鉴定 HLA-A*2402 限制性巨细胞病毒特异性 CD8(+) T 细胞表位
Blood. 2001 Sep 15;98(6):1872-81. doi: 10.1182/blood.v98.6.1872.
5
Kinase-deficient CMVpp65 triggers a CMVpp65 specific T-cell immune response in HLA-A*0201.Kb transgenic mice after DNA immunization.
Scand J Immunol. 2002 Jun;55(6):592-8. doi: 10.1046/j.1365-3083.2002.01099.x.
6
Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus.人巨细胞病毒基质蛋白pp65编码的HLA - A24限制性细胞毒性T淋巴细胞表位的鉴定
Immunol Lett. 2002 Aug 1;83(1):21-30. doi: 10.1016/s0165-2478(02)00073-1.
7
Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus.在巨细胞病毒蛋白pp65中鉴定出三个HLA-A*0201限制性细胞毒性T细胞表位，这些表位在该病毒的八个毒株之间是保守的。
J Immunol. 1999 Nov 15;163(10):5512-8.
8
Site-directed mutation in a conserved kinase domain of human cytomegalovirus-pp65 with preservation of cytotoxic T lymphocyte targeting.人巨细胞病毒pp65保守激酶结构域中的定点突变，同时保留细胞毒性T淋巴细胞靶向性。
Vaccine. 2001 Feb 8;19(13-14):1628-35. doi: 10.1016/s0264-410x(00)00423-0.
9
Induction of HLA-G-restricted human cytomegalovirus pp65 (UL83)-specific cytotoxic T lymphocytes in HLA-G transgenic mice.在HLA-G转基因小鼠中诱导HLA-G限制的人巨细胞病毒pp65（UL83）特异性细胞毒性T淋巴细胞。
J Gen Virol. 2003 Feb;84(Pt 2):307-317. doi: 10.1099/vir.0.18735-0.
10
Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation.可溶性重组 CMVpp65 跨越多个 HLA 等位基因，用于重建异基因干细胞移植后抗病毒的 CD4+和 CD8+ T 细胞反应。
J Immunother. 2010 Jan;33(1):60-72. doi: 10.1097/CJI.0b013e3181b56dcc.

引用本文的文献

1
Optimisation of the cultured ELISpot/Fluorospot technique for the selective investigation of SARS-CoV-2 reactive central memory T cells.用于选择性研究SARS-CoV-2反应性中央记忆T细胞的培养ELISpot/荧光斑点技术的优化
Front Immunol. 2025 Apr 15;16:1547220. doi: 10.3389/fimmu.2025.1547220. eCollection 2025.
2
Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice.抗人巨细胞病毒疫苗的研发：进展、障碍及对临床实践的启示
Vaccines (Basel). 2021 May 25;9(6):551. doi: 10.3390/vaccines9060551.
3
Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.用重叠十五肽致敏的供体T细胞进行免疫治疗以治疗持续性巨细胞病毒感染或病毒血症。
Biol Blood Marrow Transplant. 2015 Sep;21(9):1663-78. doi: 10.1016/j.bbmt.2015.05.015. Epub 2015 May 29.
4
Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine.新型豚鼠特异性干扰素-γ酶联免疫斑点试验的开发以及用安卡拉痘苗病毒（MVA）载体GP83疫苗免疫后豚鼠巨细胞病毒GP83特异性细胞免疫反应的特征分析
Vaccine. 2014 Jun 30;32(31):3963-70. doi: 10.1016/j.vaccine.2014.05.011. Epub 2014 May 20.
5
T cell receptor αβ diversity inversely correlates with pathogen-specific antibody levels in human cytomegalovirus infection.人类巨细胞病毒感染中 T 细胞受体 αβ 多样性与病原体特异性抗体水平呈负相关。
Sci Transl Med. 2012 Apr 4;4(128):128ra42. doi: 10.1126/scitranslmed.3003647.
6
Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.PADRE-巨细胞病毒（CMV）和破伤风-CMV 融合肽疫苗联合或不联合 PF03512676 佐剂的安全性和免疫原性临床评价。
J Infect Dis. 2012 Apr 15;205(8):1294-304. doi: 10.1093/infdis/jis107. Epub 2012 Mar 7.
7
Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies.热休克蛋白 70/肽复合物：产生抗病毒 T 细胞的有效介质，特别是针对低前体频率。
J Transl Med. 2011 Oct 12;9:175. doi: 10.1186/1479-5876-9-175.
8
Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.用三价质粒DNA和灭活鼠巨细胞病毒（MCMV）疫苗进行全身启动-加强免疫，可在全身或黏膜MCMV攻击后提供针对病毒复制的长期保护。
J Virol. 2005 Jan;79(1):159-75. doi: 10.1128/JVI.79.1.159-175.2005.

本文引用的文献

1
Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries.源自位置扫描合成组合文库的细胞毒性T淋巴细胞表位类似物的免疫活性增强。
Blood. 2001 Mar 15;97(6):1776-86. doi: 10.1182/blood.v97.6.1776.
2
Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs.健康个体中针对人巨细胞病毒pp65、IE1-外显子4、gB、pp150和pp28的细胞毒性T淋巴细胞（CTL）反应：对IE1特异性CTL流行率的重新评估
J Infect Dis. 2000 May;181(5):1537-46. doi: 10.1086/315445. Epub 2000 May 15.
3
Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus.在巨细胞病毒蛋白pp65中鉴定出三个HLA-A*0201限制性细胞毒性T细胞表位，这些表位在该病毒的八个毒株之间是保守的。
J Immunol. 1999 Nov 15;163(10):5512-8.
4
Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection.一种针对人巨细胞病毒感染的、基于HLA A*0201限制性肽的候选疫苗的研发。
Blood. 1997 Sep 1;90(5):1751-67.
5
Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.仅基于异基因骨髓移植受者无症状性肺巨细胞病毒感染进行抢先使用更昔洛韦治疗：长期随访
Biol Blood Marrow Transplant. 1995 Dec;1(2):88-93.
6
Evaluation of a quantitative plasma PCR plate assay for detecting cytomegalovirus infection in marrow transplant recipients.用于检测骨髓移植受者巨细胞病毒感染的定量血浆PCR平板检测法的评估
J Clin Microbiol. 1997 Mar;35(3):788-90. doi: 10.1128/jcm.35.3.788-790.1997.
7
The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.人类细胞毒性T淋巴细胞（CTL）对巨细胞病毒的反应以结构蛋白pp65为主导：pp65特异性CTL的频率、特异性和T细胞受体使用情况。
J Virol. 1996 Nov;70(11):7569-79. doi: 10.1128/JVI.70.11.7569-7579.1996.
8
Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells.人巨细胞病毒特异性细胞毒性T细胞对人巨细胞病毒基因产物的识别。
Virology. 1996 Aug 1;222(1):293-6. doi: 10.1006/viro.1996.0424.
9
Human cytomegalovirus pp65 lower matrix phosphoprotein harbours two transplantable nuclear localization signals.人巨细胞病毒pp65低基质磷蛋白含有两个可移植的核定位信号。
J Gen Virol. 1996 Jun;77 ( Pt 6):1151-7. doi: 10.1099/0022-1317-77-6-1151.
10
Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes.鉴定人巨细胞病毒主要晚期基质蛋白pp65作为CD8 +病毒特异性细胞毒性T淋巴细胞的靶抗原。
J Med Virol. 1994 May;43(1):103-10. doi: 10.1002/jmv.1890430119.

人巨细胞病毒分离株中，由HLA A*0201等位基因呈递的pp65(495 - 503)表位序列自然突变的发生率较低。

Infrequent occurrence of natural mutations in the pp65(495-503) epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates.

作者信息

Zaia J A, Gallez-Hawkins G, Li X, Yao Z Q, Lomeli N, Molinder K, La Rosa C, Diamond D J

机构信息

Department of Virology, Beckman Research Institute of the City of Hope, Duarte, California 91010, USA.

出版信息

J Virol. 2001 Mar;75(5):2472-4. doi: 10.1128/JVI.75.5.2472-2474.2001.

DOI:10.1128/JVI.75.5.2472-2474.2001
PMID:11160752
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC114832/
Abstract

To determine if mutations of an immunodominant HLA-restricted cytomegalovirus (CMV) peptide sequence occur in nature, the sequence corresponding to the HLA A*0201-specific peptide CMVpp65(495-503) was determined in 50 human CMV isolates. Rare mutations were detected; 6 of 50 were silent mutations at the amino terminus of the peptide, while 3 of 50 were mutations of the native methionine residue to isoleucine (M499I). The observed M499I mutation in three isolates decreased cytolytic targeting.

摘要

为了确定免疫显性的HLA限制性巨细胞病毒（CMV）肽序列的突变是否在自然情况下发生，我们在50株人CMV分离株中测定了与HLA A*0201特异性肽CMVpp65(495 - 503)相对应的序列。检测到罕见突变；50株中有6株在肽的氨基末端发生沉默突变，而50株中有3株将天然甲硫氨酸残基突变为异亮氨酸（M499I）。在三株分离株中观察到的M499I突变降低了细胞溶解靶向作用。